- Oops!Something went wrong.Please try again later.
(Reuters) - Genome sequencing company Human Longevity Inc plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1 billion, the two companies said on Monday.
The announcement followed the signing of a non-binding letter of intent, although the companies said that there is no assurance of a definitive agreement or completion of a deal.
Freedom Acquisition I Corp is a special purpose acquisition company led by former Credit Suisse chief executive Tidjane Thiam, and was listed early last year.
A blank-check firm, or a special purpose acquisition company (SPAC), is a listed shell entity that uses the money raised in its IPO to merge with a private company, taking it public in the process.
(Reporting by Leroy Leo in Bengaluru; editing by Richard Pullin)